Back to search
FDAFDA · Food and drugs·Recall number Z-1181-2024

Software VERIQA (S070031), version 2.0 and 2.1- Software package for display, evaluation and digital processing of medical image data sets and treatment plans in radiation oncology.

Published February 28, 2024 · Recall initiated: February 8, 2024

Summary

FDA records medical device Class II recall Z-1181-2024, published February 28, 2024 and initiated February 8, 2024. Recalling firm: PTW-FREIBURG; Status: Ongoing; Reported quantity: 1 US; 65 worldwide; Lot: UDI-DI: EPTWS070031 Software VERIQA (S070031), version 2.0 and 2.1. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Software: If the user excludes voxels from the Gamma calculation that are below a dose threshold (Suppress gamma calculation), the Gamma Passing Rate (GPR) calculated for individual ROIs is not correct. The GPR calculated by VERIQA overestimates the correct GPR. The evaluation can therefore show false positive results.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
PTW-FREIBURG
Distributor
GA
Lot
UDI-DI: EPTWS070031 Software VERIQA (S070031), version 2.0 and 2.1
Risk classification
Class II
Area (FDA)
device
Country
Germany

Related recalls

Questions about this recall

Was Software VERIQA (S070031), version 2.0 and 2.1- Software package for display, evaluation and digital processing of medical image data sets and treatment plans in radiation oncology. recalled?

Yes. FDA published recall Z-1181-2024 on February 28, 2024. Reported hazard: Software: If the user excludes voxels from the Gamma calculation that are below a dose threshold (Suppress gamma calculation), the Gamma Passing Rate (GPR) calculated for individual ROIs is not correct. The GPR calculated by VERIQA overestimates the correct GPR. The evaluation can therefore show false positive results.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail